Tobin W. Juvenal
Equibles does not estimate personal net worth.
Get an email with a short summary when Castle Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get CSTL alertsAbout Tobin W. Juvenal
The proxy statement of Castle Biosciences Inc reports total compensation of $2,446,931 for Tobin W. Juvenal in fiscal 2024, including a base salary of $506,415. Disclosed compensation is on record for 4 fiscal years. Castle Biosciences Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Castle Biosciences Inc includes Derek Maetzold (CEO and Board Member), Frank Stokes (CFO), Kristen M. Oelschlager (COO) and 3 others.
Affiliation history
-
Castle Biosciences Inc (CSTL)
Proxy statement
CurrentStart not stated–present
Last confirmed April 8, 2026
Company network
Leadership on record at Castle Biosciences Inc
- Derek Maetzold CEO, Board Member
- Frank Stokes CFO
- Kristen M. Oelschlager COO
- Kimberlee Caple Board Member
- Miles Harrison Board Member
- Rodney Cotton Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Castle Biosciences Inc (CSTL) | Chief Commercial Officer | $506,415 | $2,446,931 |
| 2023 | Castle Biosciences Inc (CSTL) | Chief Commercial Officer | $482,300 | $829,099 |
| 2022 | Castle Biosciences Inc (CSTL) | Chief Commercial Officer | $455,000 | $2,702,056 |
| 2021 | Castle Biosciences Inc (CSTL) | Chief Commercial Officer | $425,000 | $2,786,943 |
Recent activity
No call appearances or filed executive changes recorded yet.